Supportive care measures

Phase 3Small molecule

Supportive care measures is one of 206 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

205

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal Squamous Cell CarcinomaRecruiting

Colorectal CancerRecruiting

Non Muscle Invasive Bladder CancerRecruiting

Esophageal AdenocarcinomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Urothelial CarcinomaActive, not recruiting

Esophageal Squamous Cell CarcinomaPreclinical

Recruiting

Colorectal CancerPreclinical

Recruiting

Non Muscle Invasive Bladder CancerPreclinical

Recruiting

Esophageal AdenocarcinomaPhase 3

Active, not recruiting

Non-Small Cell Lung CancerPhase 3

Active, not recruiting

Urothelial CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

KN046

JJiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 3

4 2

Supportive care measures

Merck & Co.

Phase 3

1 3

YL202

MMediLink Therapeutics (Suzhou) Co., Ltd.

Phase 3

2 4

Eftilagimod Alfa

IImmutep S.A.S.

Phase 3

1 5

Remeron

OOrganon and Co

Preclinical

1 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 10

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Active, not recruiting

Esophageal Adenocarcinoma

NCT06356311

Q1 2028

Phase 1Active, not recruiting

Non-Small Cell Lung Cancer

NCT06049212

Phase 1/2Active, not recruiting

Urothelial Carcinoma

NCT06483334

Q1 2029

PreclinicalRecruiting

Non Muscle Invasive Bladder Cancer

NCT06637423

Q2 2029

PreclinicalRecruiting

Esophageal Squamous Cell Carcinoma

NCT05319730

Clinical

Trials by Indication[1]

Urothelial Carcinoma1 trial

A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT06483334·38 enrolled

Esophageal Adenocarcinoma1 trial

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06356311·450 enrolled

Non-small Cell Lung Cancer (NSCLC)1 trial

A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% (TroFuse-007)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06170788·614 enrolled

Colorectal Cancer1 trial

A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06428409·220 enrolled

Non-Small Cell Lung Cancer1 trial

Phase 1 Trial of MK-2870 as Monotherapy and in Combination With Pembrolizumab ± Chemotherapy in Subjects With Advanced Solid Tumors

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 1·NCT06049212·30 enrolled

2 more indications

Esophageal Squamous Cell Carcinoma1 trial

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06B

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT05319730·230 enrolled

Non Muscle Invasive Bladder Cancer1 trial

A Phase 1/2 Open-label Clinical Study to Evaluate the Safety and Efficacy of Intravesical Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06637423·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Supportive care measures. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Supportive care measures compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Supportive care measures. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

Supportive care measures

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q1 2028

Q1 2029

Q2 2029

Trials by Indication[1]

Urothelial Carcinoma1 trial

Esophageal Adenocarcinoma1 trial

Non-small Cell Lung Cancer (NSCLC)1 trial

Colorectal Cancer1 trial

Non-Small Cell Lung Cancer1 trial

Esophageal Squamous Cell Carcinoma1 trial

Non Muscle Invasive Bladder Cancer1 trial

References

Drug Info

Quick Facts

Related News